At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
Lenvatinibdrug
Likely dose
Lenvatinib 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy and Safety of Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer
In Brief
A Phase 2 clinical trial evaluating Lenvatinib for Cholangiocarcinoma and 2 related conditions. Completed, enrolled 46 participants across 1 site.
Detailed Summary
This is a single center, nonrandom, open-label study aiming to evluate the efficacy and safety of lenvatinib for patients with pretreated advanced biliary tract cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholangiocarcinoma, Biliary Tract Cancer, Targeted Therapy
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
Primary CompletionDec 2020
First PostedDec 2020
Study CompletionMay 2021
TodayJul 2026
First PostedDec 7, 2020
Enrollment StartJan 1, 2018
Primary CompletionDec 1, 2020
Study CompletionMay 1, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.6 years ago
Interventions
Lenvatinibdrug
Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing \<60 kg and 12mg/d to those ≥60 kg.